Seagen Inc. today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® in combination with the antibody-drug conjugate ado-trastuzumab emtansine met its primary endpoint of. -Today at 08:06 am- MarketScreener
BOTHELL, Wash. (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had u.
Clarity commences COMBAT theranostic prostate cancer trial in the US asiabulletin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiabulletin.com Daily Mail and Mail on Sunday newspapers.
Clarity commences COMBAT theranostic prostate cancer trial in the US sydneysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sydneysun.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products.